AbbVie Submits SKYRIZI SC Induction Application to EMA
North Chicago, Illinois, United States, Aug. 27, 2026 AbbVie has submitted a regulatory application to the European Medicines Agency...
EMA
Advertisement
Daiichi Sankyo, AstraZeneca Advance Datroway in Phase 3 Urothelial Cancer Trial
Tokyo, August 26, 2026 Daiichi Sankyo announced that the first patient has been dosed in TROPION-Urothelial04, a global Phase...
INmune Bio Advances Ebstrocel Toward EU Marketing Filing
BOCA RATON, Fla., Aug. 26, 2026 INmune Bio Inc. has advanced Ebstrocel™ toward potential European commercialization after submitting two...
Vanda Pharmaceuticals Gains EU Orphan Status for Imsidolimab
Washington, D.C., August 24, 2026 Vanda Pharmaceuticals Inc. announced that the European Commission has granted Orphan Designation to imsidolimab...
Pfizer and Valneva Secure EMA Validation for Lyme Vaccine
NEW YORK and LYON, France, August 14, 2026 Pfizer Inc. and Valneva SE announced that the European Medicines Agency...
Advertisements
Annexon Expands Phase 3 ARCHER II Trial in Geographic Atrophy
BRISBANE, Calif., August 12, 202 Annexon, Inc. announced the expansion of its ongoing Phase 3 ARCHER II trial evaluating...
LeonaBio Advances Lasofoxifene in Metastatic Breast Cancer
BOTHELL, Wash., August 12, 2026 LeonaBio, Inc. announced that its lead investigational therapy lasofoxifene will be featured in multiple...
Can-Fite Advances Phase III Programs With FDA and EMA Status
RAMAT GAN, Israel, August 12, 2026 Can-Fite BioPharma Ltd. announced an update on the regulatory status of its two...
Curium Acquires Abscint to Expand Oncology PET Pipeline
Boston, Mass. & Liège, Belgium, August 10, 2026 Curium announced the completion of its acquisition of Abscint SA, a...
Tenax Therapeutics Reports Phase 3 LEVEL Results for TNX-103
Chapel Hill, N.C., August 10, 2026 Tenax Therapeutics, Inc. announced topline results from the Phase 3 LEVEL clinical trial...
Advertisement
